Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

tetra logo

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Guy Chamberland

 

 

 

 

 

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.

Investor Presentation Deck

Tetra Investor Presentation




Related Articles

CEO Interview

Village Farms International (TSX: VFF:) CEO Michael DeGiglio discusses expansion into cannabis market.

January 19, 2018 admin CEO Interview, Consumer Comments Off on Village Farms International (TSX: VFF:) CEO Michael DeGiglio discusses expansion into cannabis market.

Village Farms International (TSX: VFF:) CEO Michael DeGiglio discusses the greenhouse growing company’s expansion into the cannabis market. Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. […]

CEO Interview

CytoDyn Inc. (OTC: CYDY) HIV therapy nearing FDA approval + drug pipeline with blockbuster potential

July 16, 2019 admin CEO Interview, Healthcare, Spotlight Stocks Comments Off on CytoDyn Inc. (OTC: CYDY) HIV therapy nearing FDA approval + drug pipeline with blockbuster potential

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

Healthcare

CytoDyn (OTC: CYDY) Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

August 8, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Aug. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]